Tags

Type your tag names separated by a space and hit enter

Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Oncol Rep. 2004 Jun; 11(6):1153-9.OR

Abstract

The purpose of this study was to examine human kallikrein 8 (hK8/TADG-14) expression in epithelial ovarian tumors and to investigate the association of hK8 expression levels with patient survival. Human kallikrein 8 protein (hK8) expression was examined by immunohistochemistry in 74 ovarian adenocarcinomas and 6 normal ovaries. Results of immunostaining were correlated with clinicopathological variables and overall survival of the patients. Human kallikrein 8 gene (KLK8) mRNA expression was examined by semi-quantitative PCR in 35 ovarian tumors and 7 normal ovaries. Expression of hK8 was not detected on the surface epithelium of normal ovaries. In contrast, hK8 expression was detected in 51.4% (38/74) of carcinomas with a significantly higher detection rate of hK8 expression being observed in early stage disease compared to advanced stage disease (p=0.0192). Data analysis using the log-rank test showed hK8 expression correlated significantly with favorable patient survival (p=0.0328). Younger age (p=0.0008), early clinical stage (p<0.0001), and low histological grades of the tumors (p=0.0018) were also associated significantly with a favorable prognosis. In a multivariate model, age (p=0.0186) and clinical stage (p<0.0001) remained associated significantly with overall survival, whereas hK8 expression and histological grade lost their significance. There was significant relationship between the hK8 expression status and KLK8 mRNA expression levels (p=0.0304). Expression of hK8 is increased during the development of ovarian cancer and down-regulated during ovarian cancer progression. Expression of hK8 is a favorable prognostic marker in patients with ovarian cancer.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Hiroshima University Graduate School of Biomedical Sciences, Minami-ku, Hiroshima 734-8551, Japan. kazu@hiroshima-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15138549

Citation

Shigemasa, Kazushi, et al. "Human Kallikrein 8 (hK8/TADG-14) Expression Is Associated With an Early Clinical Stage and Favorable Prognosis in Ovarian Cancer." Oncology Reports, vol. 11, no. 6, 2004, pp. 1153-9.
Shigemasa K, Tian X, Gu L, et al. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep. 2004;11(6):1153-9.
Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L. J., O'Brien, T. J., & Ohama, K. (2004). Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncology Reports, 11(6), 1153-9.
Shigemasa K, et al. Human Kallikrein 8 (hK8/TADG-14) Expression Is Associated With an Early Clinical Stage and Favorable Prognosis in Ovarian Cancer. Oncol Rep. 2004;11(6):1153-9. PubMed PMID: 15138549.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. AU - Shigemasa,Kazushi, AU - Tian,Xiurong, AU - Gu,Lijun, AU - Tanimoto,Hirotoshi, AU - Underwood,Lowell J, AU - O'Brien,Timothy J, AU - Ohama,Koso, PY - 2004/5/13/pubmed PY - 2004/12/16/medline PY - 2004/5/13/entrez SP - 1153 EP - 9 JF - Oncology reports JO - Oncol. Rep. VL - 11 IS - 6 N2 - The purpose of this study was to examine human kallikrein 8 (hK8/TADG-14) expression in epithelial ovarian tumors and to investigate the association of hK8 expression levels with patient survival. Human kallikrein 8 protein (hK8) expression was examined by immunohistochemistry in 74 ovarian adenocarcinomas and 6 normal ovaries. Results of immunostaining were correlated with clinicopathological variables and overall survival of the patients. Human kallikrein 8 gene (KLK8) mRNA expression was examined by semi-quantitative PCR in 35 ovarian tumors and 7 normal ovaries. Expression of hK8 was not detected on the surface epithelium of normal ovaries. In contrast, hK8 expression was detected in 51.4% (38/74) of carcinomas with a significantly higher detection rate of hK8 expression being observed in early stage disease compared to advanced stage disease (p=0.0192). Data analysis using the log-rank test showed hK8 expression correlated significantly with favorable patient survival (p=0.0328). Younger age (p=0.0008), early clinical stage (p<0.0001), and low histological grades of the tumors (p=0.0018) were also associated significantly with a favorable prognosis. In a multivariate model, age (p=0.0186) and clinical stage (p<0.0001) remained associated significantly with overall survival, whereas hK8 expression and histological grade lost their significance. There was significant relationship between the hK8 expression status and KLK8 mRNA expression levels (p=0.0304). Expression of hK8 is increased during the development of ovarian cancer and down-regulated during ovarian cancer progression. Expression of hK8 is a favorable prognostic marker in patients with ovarian cancer. SN - 1021-335X UR - https://www.unboundmedicine.com/medline/citation/15138549/Human_kallikrein_8__hK8/TADG_14__expression_is_associated_with_an_early_clinical_stage_and_favorable_prognosis_in_ovarian_cancer_ L2 - http://www.spandidos-publications.com/or/11/6/1153 DB - PRIME DP - Unbound Medicine ER -